Abstract
Bone metastases are a common problem of many malignancies, including myeloma, breast and prostate cancer. The Wnt inhibitor Dickkopf-1 has been shown to be involved in the process of bone lesions by impairing osteoblast activity. This review will focus on the role of Dickkopf-1 as a mediator of malignant bone disease and discuss its potential as a novel therapeutic target.
Keywords:
Dickkopf-1; Malignant bone disease; WNT signaling.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / metabolism*
-
Bone Neoplasms / secondary*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology
-
Clinical Trials as Topic
-
Female
-
Humans
-
Intercellular Signaling Peptides and Proteins / immunology
-
Intercellular Signaling Peptides and Proteins / metabolism*
-
Male
-
Molecular Targeted Therapy
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / metabolism
-
Multiple Myeloma / pathology
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / metabolism
-
Prostatic Neoplasms / pathology
Substances
-
Antibodies, Monoclonal
-
DKK1 protein, human
-
Dkk1 protein, mouse
-
Intercellular Signaling Peptides and Proteins